Waters Secures FDA Clearance for BD BACTEC FXI System, Enhancing Sepsis Diagnostics
WAT sits 37% above its 52-week low of $275.05.
Summary
Waters Corporation announced FDA 510(k) clearance for its BD BACTEC FXI Culture System, enabling U.S. commercialization. This product, likely part of the recently acquired BD Biosci assets as noted in the March 16th 8-K, significantly improves bloodstream infection diagnostics. It offers a 3-hour faster time to detection for sepsis and a 50% increase in vial loading capacity, enhancing laboratory efficiency and patient care.
At the time of this announcement, WAT was trading at $378.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.5B. The 52-week trading range was $275.05 to $414.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.